EA201070656A1 - Способ задержки начала проявления клинически определенного рассеянного склероза - Google Patents

Способ задержки начала проявления клинически определенного рассеянного склероза

Info

Publication number
EA201070656A1
EA201070656A1 EA201070656A EA201070656A EA201070656A1 EA 201070656 A1 EA201070656 A1 EA 201070656A1 EA 201070656 A EA201070656 A EA 201070656A EA 201070656 A EA201070656 A EA 201070656A EA 201070656 A1 EA201070656 A1 EA 201070656A1
Authority
EA
Eurasian Patent Office
Prior art keywords
multiple sclerosis
clinically defined
manifestation
delaying
beginning
Prior art date
Application number
EA201070656A
Other languages
English (en)
Inventor
Яфит Старк
Давид Ладкани
Original Assignee
Тева Фармасьютикал Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40678899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201070656(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Тева Фармасьютикал Индастриз, Лтд. filed Critical Тева Фармасьютикал Индастриз, Лтд.
Publication of EA201070656A1 publication Critical patent/EA201070656A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Раскрыт способ задержки начала проявления клинически определенного рассеянного склероза у пациента, имеющего риск развития клинически определенного рассеянного склероза, а также пролонгированной задержки прогрессирования рассеянного склероза и его симптомов, где указанный способ включает периодическое введение указанному пациенту фармацевтической композиции, содержащей терапевтически эффективное количество ацетата глатимера, приводящей к задержке развития клинически определенного рассеянного склероза и к пролонгированной задержке прогрессирования рассеянного склероза и его симптомов.
EA201070656A 2007-11-28 2008-11-26 Способ задержки начала проявления клинически определенного рассеянного склероза EA201070656A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US471007P 2007-11-28 2007-11-28
US527107P 2007-12-03 2007-12-03
US714107P 2007-12-11 2007-12-11
US19245508P 2008-09-17 2008-09-17
PCT/US2008/013146 WO2009070298A1 (en) 2007-11-28 2008-11-26 Method of delaying the onset of clinically definite multiple sclerosis

Publications (1)

Publication Number Publication Date
EA201070656A1 true EA201070656A1 (ru) 2010-12-30

Family

ID=40678899

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070656A EA201070656A1 (ru) 2007-11-28 2008-11-26 Способ задержки начала проявления клинически определенного рассеянного склероза

Country Status (12)

Country Link
US (2) US20090149541A1 (ru)
EP (1) EP2111105A4 (ru)
JP (1) JP2011504925A (ru)
KR (1) KR20100102620A (ru)
CN (1) CN101877963A (ru)
AU (1) AU2008330093A1 (ru)
BR (1) BRPI0819001A2 (ru)
CA (1) CA2702437C (ru)
EA (1) EA201070656A1 (ru)
IL (1) IL205856A0 (ru)
MX (1) MX2010005676A (ru)
WO (1) WO2009070298A1 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP2277887A3 (en) 2001-10-19 2011-02-16 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US20060172942A1 (en) * 2005-02-02 2006-08-03 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
PL1848415T3 (pl) * 2005-02-17 2013-10-31 Teva Pharma Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
ES2534044T3 (es) * 2008-11-06 2015-04-16 Vascular Biogenics Ltd. Compuestos de lípidos oxidados y usos de los mismos
JP2011010865A (ja) 2009-06-30 2011-01-20 Ikaria Holdings Inc 肺高血圧の臨床的または超音波心臓検査上の証拠を伴う低酸素性呼吸器不全に罹った満期産およびほぼ満期産の新生児を治療する方法
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
RS52367B (en) 2009-07-15 2012-12-31 Teva Pharmaceutical Industries Ltd. GLATIRAMER ACETATE FORMULATION FORMATED VOLUMES AND APPLICATION PROCEDURES
CZ29723U1 (cs) 2009-08-20 2016-08-30 Yeda Research & Development Company, Ltd. Nízkofrekvenční terapie s glatiramer acetátem
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
ES2654944T3 (es) * 2010-01-05 2018-02-15 Vascular Biogenics Ltd. Tratamiento combinado que utiliza VB-201
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
NZ609938A (en) 2010-10-11 2015-11-27 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
CN105853348B (zh) 2011-03-10 2019-08-30 Xeris药物公司 肠胃外注射用稳定溶液
CA2851510A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
KR102007057B1 (ko) 2011-10-31 2019-08-02 엑스에리스 파머수티클스, 인크. 당뇨병 치료를 위한 제형물
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
NZ630421A (en) 2012-10-10 2018-07-27 Teva Pharma Biomarkers predictive for clinical response for glatiramer acetate
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
EP3185932A1 (en) 2014-08-06 2017-07-05 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
ES2855299T3 (es) 2014-11-26 2021-09-23 Vascular Biogenics Ltd Lípidos oxidados y tratamiento o prevención de la fibrosis
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
JP7299166B2 (ja) 2017-06-02 2023-06-27 ゼリス ファーマシューティカルズ インコーポレイテッド 沈殿抵抗性低分子薬物製剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
EP1098902A4 (en) * 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) * 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
CN100360180C (zh) * 2000-01-20 2008-01-09 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
ZA200206457B (en) * 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
PT1459065E (pt) * 2001-12-04 2010-10-11 Teva Pharma Processos para a medição da potência do acetato de glatirâmero
US20040048871A1 (en) * 2002-09-09 2004-03-11 Rowe Vernon D. Use of high dose intravenous methotrexate, with leucovorin rescue, to treat early multiple sclerosis and other diseases of the central nervous system
AU2004285553B2 (en) * 2003-10-31 2009-12-10 Teva Pharmaceutical Industries, Ltd. Nanoparticles for drug delivery
US20050220764A1 (en) * 2004-04-01 2005-10-06 Schering Aktiengesellschaft Higher-doses of interferon-beta for treatment of multiple sclerosis
WO2005108610A2 (en) * 2004-04-05 2005-11-17 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for the selection of subjects for multiple sclerosis therapy
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
KR101317131B1 (ko) * 2004-09-09 2013-10-10 테바 파마슈티컬 인더스트리즈 리미티드 정제된 브롬화 수소산을 이용한 폴리펩타이드류의 혼합물의제조방법
US20060172942A1 (en) * 2005-02-02 2006-08-03 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
US20060240463A1 (en) * 2005-04-25 2006-10-26 Rappaport Family Institute For Research In The Medical Sciences Markers associated with the therapeutic efficacy of glatiramer acetate
US20070161566A1 (en) * 2006-01-11 2007-07-12 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis

Also Published As

Publication number Publication date
MX2010005676A (es) 2010-08-06
EP2111105A1 (en) 2009-10-28
AU2008330093A1 (en) 2009-06-04
IL205856A0 (en) 2010-11-30
KR20100102620A (ko) 2010-09-24
BRPI0819001A2 (pt) 2014-10-07
CA2702437C (en) 2013-06-25
CA2702437A1 (en) 2009-06-04
WO2009070298A9 (en) 2010-07-01
JP2011504925A (ja) 2011-02-17
US20100305023A1 (en) 2010-12-02
US20090149541A1 (en) 2009-06-11
CN101877963A (zh) 2010-11-03
EP2111105A4 (en) 2011-05-04
WO2009070298A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
EA201070656A1 (ru) Способ задержки начала проявления клинически определенного рассеянного склероза
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
EA201390332A1 (ru) Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
EA200501421A1 (ru) Пероральная композиция инсулина и способы её изготовления и применения
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
EA201201265A1 (ru) Композиция (варианты), способ ее получения, резервуар, содержащий указанную композицию, и способ лечения вирусных заболеваний с ее использованием
EA201490876A1 (ru) Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
MD20130095A2 (ru) Конденсированные соединения бензоксазепинонов в качестве модуляторов ионных каналов
WO2011106573A3 (en) Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
EA201391532A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
EA201100245A1 (ru) Новый холиновый сокристалл эпалрестата
EA201590726A1 (ru) Лахинимод для уменьшения таламического поражения при рассеянном склерозе
EA201690899A1 (ru) Оксазепины в качестве модуляторов ионных каналов
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MY178654A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy
EA201171285A1 (ru) Новая технология изготовления диклофенака
EA200971053A1 (ru) Способы лечения кожных язв
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
MX2014005996A (es) Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia.
EA200970435A1 (ru) Лечение общих расстройств развития
EA200800303A1 (ru) Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами